Clinical Trial of Investigational Drug for PancreaticCancer

siteman.wustl.edu — The U.S. Food and Drug Administration (FDA) has approved a phase I clinical trial of the drug IMP321 in the treatment of advanced pancreatic cancer. The trial is being conducted by surgeon William Hawkins, MD, at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.